Comparison of the therapeutic response to treatment with a 177Lu-labeled somatostatin receptor agonist and antagonist in preclinical models

Journal of Nuclear Medicine

Volumn 57, Issue 2, 2016, Pages 260-265

  Dalm, Simone U ^a   Nonnekens, Julie ^a   Doeswijk, Gabriela N ^a   De Blois, Erik ^a   Van Gent, DIk C ^a   Konijnenberg, Mark W ^a   De Jong, Marion ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Agonist; Antagonist; PRRT; Somatostatin receptor; Therapy

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN P53; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR AGONIST; SOMATOSTATIN RECEPTOR ANTAGONIST; TETRAXETAN JR 11 LU 177; TETRAXETAN OCTREOTATE LU 177; UNCLASSIFIED DRUG; 177LU-DOTA-JR11; 177LU-DOTA-OCTREOTATE; COORDINATION COMPOUND; CYCLOPEPTIDE; OCTREOTIDE; RADIOPHARMACEUTICAL AGENT; SIGNAL PEPTIDE; SOMATOSTATIN RECEPTOR SUBTYPE 2, HUMAN; TP53BP1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; COMPARATIVE STUDY; CONTROLLED STUDY; DOSIMETRY; DOUBLE STRANDED DNA BREAK; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RESPONSE; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MALE; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; OSTEOSARCOMA CELL LINE; PRIORITY JOURNAL; RADIATION DOSE; SURVIVAL RATE; TUMOR VOLUME; TUMOR XENOGRAFT; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; DNA DAMAGE; DRUG SCREENING; METABOLISM; NEUROENDOCRINE TUMORS; RADIOMETRY; SURVIVAL ANALYSIS; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; COORDINATION COMPLEXES; DNA DAMAGE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED BALB C; NEUROENDOCRINE TUMORS; OCTREOTIDE; PEPTIDES, CYCLIC; RADIOMETRY; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; SURVIVAL ANALYSIS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84958590355     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.167007     Document Type: Article

References (23)

1. Krenning EP, Bakker WH, Breeman WA, et al. Localisation of endocrinerelated tumours with radioiodinated analogue of somatostatin. Lancet. 1989;1: 242-244.
2. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005;46(suppl 1):62S-66S.
3. Bergsma H, van Vliet EI, Teunissen JJ, et al. Peptide receptor radionuclide therapy (PRRT) for GEP-NETs. Best Pract Res Clin Gastroenterol. 2012;26: 867-881.
4. Bison SM, Konijnenberg M, Melis M, et al. Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments. Clin Transl Imaging. 2014;2:55-66.
5. Ginj M, Zhang H, Waser B, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA. 2006;103:16436-16441.
6. 177Lu-DOTA-sst2 agonist binDing in human cancers in vitro. J Nucl Med. 2011;52:1886-1890.
7. Wild D, Fani M, Behe M, et al. First clinical evidence that imaging with somatostatin receptor antagonists is feasible. J Nucl Med. 2011;52:1412-1417.
8. Wild D, Fani M, Fischer R, et al. Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study. J Nucl Med. 2014;55:1248-1252.
9. Fani M, Braun F, Waser B, et al. Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications. J Nucl Med. 2012;53:1481-1489.
10. 177Lu-labelled somatostatin analogs. Appl Radiat Isot. 2014;85:28-33.
11. 177Lu-labelled methionine-containing regulatory peptides: maintaining radiochemical purity as measured by HPLC. Curr Top Med Chem. 2012;12:2677-2685.
12. Wyman C, Kanaar R. DNA double-strand break repair: all's well that ends well. Annu Rev Genet. 2006;40:363-383.
13. van Eerd JE, Vegt E, Wetzels JF, et al. Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats. J NuclMed. 2006;47: 528-533.
14. Keenan MA, Stabin MG, Segars WP, Fernald MJ. RADAR realistic animal model series for dose assessment. J Nucl Med. 2010;51:471-476.
15. Stabin MG, Konijnenberg MW. Re-evaluation of absorbed fractions for photons and electrons in spheres of various sizes. J Nucl Med. 2000;41:149-160.
16. Löbrich M, Shibata A, Beucher A, et al. gammaH2AX foci analysis for monitoring DNA double-strand break repair: strengths, limitations and optimization. Cell Cycle. 2010;9:662-669.
17. Barnard S, Bouffler S, Rothkamm K. The shape of the radiation dose response for DNA double-strand break induction and repair. Genome Integr. 2013; 4:1-8.
18. Vaziri B, Wu H, Dhawan AP, Du P, Howell RW, Committee SM. MIRD pamphlet No. 25: MIRDcell V2.0 software tool for dosimetric analysis of biologic response of multicellular populations. J Nucl Med. 2014;55:1557-1564.
19. Schroeder RP, Müller C, Reneman S, et al. A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues. Eur J Nucl Med Mol Imaging. 2010;37:1386-1396.
20. Tulipano G, Soldi D, Bagnasco M, et al. Characterization of new selective somatostatin receptor subtype-2 (sst2) antagonists, BIM-23627 and BIM-23454. Effects of BIM-23627 on GH release in anesthetized male rats after short-term high-dose dexamethasone treatment. Endocrinology. 2002;143:1218-1224.
21. Reubi C, Gugger M, Waser B. Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2002;29:855-862.
22. Skanberg J, Ahlman H, Benjegard S, et al. Indium-111-octreotide scintigraphy, intraoperative gamma-detector localisation and somatostatin receptor expression in primary human breast cancer. Breast Cancer Res Treat. 2002; 74:101-111.
23. Van Den Bossche B, van Belle S, de Winter F, Signore A, van de Wiele C. Early prediction of endocrine therapy effect in advanced breast cancer patients using 99mTc-depreotide scintigraphy. J Nucl Med. 2006;47:6-13.